Key Points
- Ultragenyx CFO Howard Horn sold 4,653 shares on June 1 at an average price of $23.77, for total proceeds of about $110,602. After the transaction, he still held 105,689 shares valued at roughly $2.51 million.
- The company recently missed Q1 earnings expectations, reporting an EPS loss of $1.84 versus the expected $1.49 loss and revenue of $136 million, below the $158.19 million consensus estimate.
- Wall Street remains cautiously positive overall, with an average rating of “Moderate Buy” and a consensus price target of $59.56, despite some recent analyst target cuts and rating changes.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 4,653 shares of the business's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $23.77, for a total transaction of $110,601.81. Following the sale, the chief financial officer owned 105,689 shares of the company's stock, valued at approximately $2,512,227.53. The trade was a 4.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Howard Horn also recently made the following trade(s):
- On Friday, May 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $24.90, for a total transaction of $116,606.70.
- On Wednesday, April 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $20.97, for a total transaction of $98,202.51.
- On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.40, for a total transaction of $36,624.00.
Ultragenyx Pharmaceutical Price Performance
RARE stock opened at $22.85 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.29 and a 1-year high of $42.37. The firm has a fifty day moving average price of $23.47 and a two-hundred day moving average price of $25.71. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of -3.74 and a beta of 0.39.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The business had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The firm's revenue for the quarter was down 2.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.57) EPS. As a group, analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.62 EPS for the current fiscal year.
Institutional Investors Weigh In On Ultragenyx Pharmaceutical
A number of institutional investors and hedge funds have recently bought and sold shares of RARE. Assetmark Inc. lifted its holdings in Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 1,024 shares during the last quarter. Huntington National Bank lifted its holdings in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 393 shares during the last quarter. Parallel Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 1,440 shares during the last quarter. Leonteq Securities AG lifted its holdings in Ultragenyx Pharmaceutical by 288.5% in the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 1,333 shares during the last quarter. Finally, Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $39,000. 97.67% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on RARE shares. The Goldman Sachs Group lowered shares of Ultragenyx Pharmaceutical from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $61.00 to $25.00 in a research report on Tuesday, March 24th. Truist Financial upgraded shares of Ultragenyx Pharmaceutical to a "strong-buy" rating in a research report on Wednesday, March 25th. Guggenheim lowered their price target on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a "buy" rating for the company in a research report on Friday, May 8th. Barclays lowered their price target on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an "overweight" rating for the company in a research report on Wednesday, April 29th. Finally, Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and an average price target of $59.56.
View Our Latest Report on Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Company Profile
(
Get Free Report)
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
